Full Spectrum Microbiota

BIOLOGICAL2 trials

Sponsors

Finch Research and Development LLC., Arizona State University

Conditions

Autism Spectrum DisorderClostridium Difficile Infection RecurrenceGastrointestinal Disorder

Phase 2

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

CompletedNCT03110133

Finch Research and Development LLC.Clostridium Difficile Infection Recurrence

Start: 2017-05-08End: 2020-06-18Updated: 2022-10-05

Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders

Active, not recruitingNCT03408886

Arizona State UniversityAutism Spectrum Disorder, Gastrointestinal Disorder

Start: 2018-01-04End: 2024-12-15Updated: 2023-01-09

Related Papers

Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial.

2024-10-0210 citations